Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Azathioprine
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Azathioprine 50mg tablets
0802010G0AAAEAE
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 92,166 |
|
Azathioprine 25mg tablets
0802010G0AAADAD
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 45,389 |
|
Azathioprine 100mg tablets
0802010G0AACNCN
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 1,529 |
|
Azathioprine 75mg tablets
0802010G0AACMCM
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 739 |
|
Azathioprine 50mg/5ml oral suspension
0802010G0AACHCH
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 232 |
|
Azathioprine 50mg/5ml oral suspension sugar free
0802010G0AACPCP
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 71 |
|
Azathioprine 50mg/5ml oral solution
0802010G0AAAPAP
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 68 |
|
Azathioprine 100mg/5ml oral suspension
0802010G0AACJCJ
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 63 |
|
Azathioprine 25mg/5ml oral suspension
0802010G0AACICI
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 46 |
|
Azathioprine 20mg/5ml oral suspension
0802010G0AACKCK
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 14 |
|
Azathioprine 10mg capsules
0802010G0AAAHAH
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 8 |
|
Azathioprine 25mg/5ml oral solution
0802010G0AAASAS
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 6 |
|
Azathioprine 250mg/5ml oral liquid
0802010G0AACGCG
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 3 |
|
Azathioprine 30mg/5ml oral liquid
0802010G0AABCBC
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 2 |
|
Azathioprine 75mg/5ml oral liquid
0802010G0AAATAT
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 2 |
|
Azathioprine 200mg/5ml oral liquid
0802010G0AABIBI
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 1 |
|
Azathioprine 100mg/5ml oral solution
0802010G0AAAVAV
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 10mg/5ml oral liquid
0802010G0AAARAR
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 120mg/5ml oral liquid
0802010G0AABXBX
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 125mg/5ml oral liquid
0802010G0AAAXAX
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 12mg/5ml oral liquid
0802010G0AABSBS
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 13mg/5ml oral liquid
0802010G0AACECE
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 150mg/5ml oral liquid
0802010G0AABYBY
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 15mg/5ml oral liquid
0802010G0AAAUAU
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 17.5mg/5ml oral liquid
0802010G0AABDBD
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.